From the Editor

Jan 21, 2014
Pharmaceutical Executive
Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exst. Drugs were still classified as chemicals, developed from the random screening of many thoughts.
Dec 01, 2013
Pharmaceutical Executive
New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry's business model.
Nov 01, 2013
Pharmaceutical Executive
Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.
Oct 01, 2013
Pharmaceutical Executive
Our October issue highlights a latent threat to Big Pharma: the behavioral mindset that may be best characterized as "ageing in place."
Sep 01, 2013
Pharmaceutical Executive
A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, lifealtering diseases.
Aug 01, 2013
Pharmaceutical Executive
The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China—ironically, the country touted as guarantor of our industry's future.
Jul 02, 2013
Pharmaceutical Executive
By Pharmaceutical Executive Editors
William Looney introduces this year's selection of 15 pharma professionals that, on our view, have real prospects for a future key to the C-suite.
Jul 01, 2013
Pharmaceutical Executive
Our lead feature this month on 15 new Emerging Pharma Leaders is a window into what makes our publication unique. In 2007, Pharm Exec began a systematic annual search to identify and highlight those men—and women—that in our purely editorial view had real prospects for a future key to the "c suite." Two of our early choices—Sanofi's Chris Viehbacher and Heather Bresch of Mylan—have made it to the very top, as CEO.
Jun 01, 2013
Pharmaceutical Executive
Getting patients to take their medicine on spec and on time is the challenge that never goes away—it's the deadweight baggage accompanying every industry innovation since the arrival of aspirin a century ago.
May 01, 2013
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Last month's decision by India's Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve—but the implications in and beyond India are both immediate and lasting.
native1_300x100
lorem ipsum